Business Description
MBX Biosciences Inc
NAICS : 541714
SIC : 2834
ISIN : US55287L1017
Total Employee Number:
63Description
MBX Biosciences Inc is a clinical stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. The company designed its proprietary Precision Endocrine Peptide, or PEP, platform to overcome the key limitations of unmodified and modified peptide therapies to improve clinical outcomes and simplify disease management for patients. Its PEPs are selectively engineered to have optimized pharmaceutical properties, including extended time-action profiles and consistent drug concentrations with low peak-to-trough concentration ratios, consistent exposure to target tissues, and less frequent dosing. Its product candidates include canvuparatide (MBX 2109), imapextide (MBX 1416), and MBX 4291.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 792.75 | |||||
Equity-to-Asset | 0.97 | |||||
Debt-to-EBITDA | -0.01 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | N/A/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -49.2 | |||||
3-Year EPS without NRI Growth Rate | -44.4 | |||||
3-Year FCF Growth Rate | -44.7 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | -19.33 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 56.19 | |||||
9-Day RSI | 67.75 | |||||
14-Day RSI | 71.3 | |||||
3-1 Month Momentum % | 8.23 | |||||
6-1 Month Momentum % | -2.2 | |||||
12-1 Month Momentum % | 172.32 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 30.79 | |||||
Quick Ratio | 30.79 | |||||
Cash Ratio | 30.2 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -12.1 | |||||
Shareholder Yield % | -2.95 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -26.26 | |||||
ROA % | -25.24 | |||||
ROIC % | -1770.57 | |||||
3-Year ROIIC % | -1226.35 | |||||
ROC (Joel Greenblatt) % | -3738.4 | |||||
ROCE % | -29.92 | |||||
Moat Score | 5 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 6.52 | |||||
Price-to-Tangible-Book | 6.53 | |||||
EV-to-EBIT | -24.45 | |||||
EV-to-EBITDA | -24.51 | |||||
EV-to-FCF | -30.26 | |||||
| Price-to-Net-Current-Asset-Value | 6.59 | |||||
| Price-to-Net-Cash | 6.72 | |||||
Earnings Yield (Greenblatt) % | -4.09 | |||||
FCF Yield % | -2.8 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:MBX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
MBX Biosciences Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -2.2 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | 91.2 | ||
| 14-Day RSI | 71.3 | ||
| 14-Day ATR ($) | 3.734512 | ||
| 20-Day SMA ($) | 51.5795 | ||
| 12-1 Month Momentum % | 172.32 | ||
| 52-Week Range ($) | 9.63 - 66.55 | ||
| Shares Outstanding (Mil) | 47.6 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 9999 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
MBX Biosciences Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
MBX Biosciences Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-06 | In 115 days | ||
| Second quarter earnings results for 2026 | 2026-08-07 | In 24 days | ||
| General meeting for 2026 | 2026-06-04 08:00 | 30.05 (-1.57%) | ||
| Guidance call for 2026 | 2026-06-03 08:10 | 30.70 (+1.35%) | ||
| First quarter earnings results for 2026 | 2026-05-07 | 32.12 (+6.89%) | ||
| Annual report for 2025 | 2026-03-12 | 28.94 (+1.44%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-12 | 28.94 (+1.44%) | ||
| TD Cowen 46th Annual Health Care Conference | 2026-03-02 09:10 | 32.55 (-1.99%) | ||
| 36(th) Oppenheimer Annual Healthcare Life Sciences Conference | 2026-02-25 11:20 | 36.73 (-1.37%) | ||
| 44(th) Annual J.P. Morgan Healthcare Conference | 2026-01-13 18:45 | 36.47 (+13.16%) |
Show
Entries
MBX Biosciences Inc Frequently Asked Questions
What is MBX Biosciences Inc(MBX)'s stock price today?
The current price of MBX is $60.04. The 52 week high of MBX is $66.55 and 52 week low is $9.63.
When is next earnings date of MBX Biosciences Inc(MBX)?
The next earnings date of MBX Biosciences Inc(MBX) is 2026-08-07 Est..
Does MBX Biosciences Inc(MBX) pay dividends? If so, how much?
MBX Biosciences Inc(MBX) does not pay dividend.
Guru Commentaries on NAS:MBX
No articles.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on MBX Biosciences Inc
Headlines
See More- 1
Jul 13, 2026
MBX Biosciences appoints Steve Hoerter as CEO and John Smither as CFO
Seeking Alpha • 3:30pm
- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers